Infectologia

Doença mais leve com a Ômicron: é o vírus ou é a imunidade pré-existente?

20 Jan, 2022 | 23:16h

Milder disease with Omicron: is it the virus or the pre-existing immunity? – Nature Reviews Immunology

---

Como a Ômicron se dissemina tão rápido? Uma alta carga viral não é a resposta – “Dados sobre níveis virais apontam para evasão imunológica como causa da transmissibilidade da variante.”

20 Jan, 2022 | 23:15h

How does Omicron spread so fast? A high viral load isn’t the answer – Nature

---

Função cardíaca é rapidamente recuperada em crianças com síndrome inflamatória multissistêmica (MIS-C) relacionada à COVID-19.

20 Jan, 2022 | 23:14h

Comunicado de imprensa: Heart function recovered quickly in children with COVID-19-related MIS-C condition – American Heart Association

Estudo original: Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated With COVID‐19 Infections – Journal of the American Heart Association

---

Revisão breve | Fluvoxamina para pacientes ambulatoriais sintomáticos com COVID-19.

20 Jan, 2022 | 23:12h

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Conteúdos relacionados:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

---

Amplo estudo observacional mostrou que pessoas com disfunção imunológica (HIV, transplante de órgão sólido, artrite reumatoide) estão sob risco aumentado de infecção por Covid-19 após a vacinação.

20 Jan, 2022 | 23:11h

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US – JAMA Internal Medicine

---

Depois da Ômicron, poderíamos ter uma pausa. Talvez tenhamos.

20 Jan, 2022 | 23:10h

After Omicron, we could use a break. We may just get it – STAT

---

10 lições aprendidas com a pandemia de Covid-19.

20 Jan, 2022 | 23:09h

10 lessons I’ve learned from the Covid–19 pandemic – STAT

---

OMS afirma que a pandemia de Covid “está longe do fim”.

20 Jan, 2022 | 23:07h

Covid pandemic ‘nowhere near over,’ WHO says – CNN

---

Análise sistemática | Impacto global da resistência bacteriana a antibióticos em 2019.

20 Jan, 2022 | 23:06h

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet

Comunicado de imprensa: An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria – The Lancet

Editorial: Antimicrobial resistance: time to repurpose the Global Fund – The Lancet

Comentário: Antimicrobial resistance now a leading cause of death worldwide, study finds – The Guardian

 

Comentário no Twitter

NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria.#GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: https://t.co/2h5UEKemEq #AMRSOS pic.twitter.com/aWLhmdirJ8

— The Lancet (@TheLancet) January 20, 2022

 

---

Estudo randomizado | Entre pacientes com infecção recorrente por Clostridioides difficile, o uso de SER-109, uma terapia de microbioma oral, reduziu a taxa de recorrência em comparação ao placebo (12% vs. 40%).

20 Jan, 2022 | 23:02h

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection – New England Journal of Medicine (link para o resumo – $ para o texto completo)

---